Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease

Immunotherapy; Neuroblastoma; Relapse

Detalles Bibliográficos
Autores: Martinez de las Heras, Blanca, Rubio-Aparicio, Pedro M, Mazorra Roig, Paula, López Almaraz, Ricardo, RUBIO-SAN-SIMON, Alba, Moreno, Lucas
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/13792
Acceso en línea:http://hdl.handle.net/11351/13792
Access Level:acceso abierto
Palabra clave:Infants
Neuroblastoma - Tractament
Neuroblastoma - Recaiguda
NAMED GROUPS::Persons::Age Groups::Child
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma
Other subheadings::Other subheadings::/therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma
Otros calificadores::Otros calificadores::/terapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
id ES_18f0f6cf2ada70fe5488b23a2cbafe06
oai_identifier_str oai:scientiasalut.gencat.cat:11351/13792
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
title Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
spellingShingle Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
Martinez de las Heras, Blanca
Infants
Neuroblastoma - Tractament
Neuroblastoma - Recaiguda
NAMED GROUPS::Persons::Age Groups::Child
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma
Other subheadings::Other subheadings::/therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma
Otros calificadores::Otros calificadores::/terapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
title_short Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
title_full Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
title_fullStr Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
title_full_unstemmed Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
title_sort Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease
dc.creator.none.fl_str_mv Martinez de las Heras, Blanca
Rubio-Aparicio, Pedro M
Mazorra Roig, Paula
López Almaraz, Ricardo
RUBIO-SAN-SIMON, Alba
Moreno, Lucas
author Martinez de las Heras, Blanca
author_facet Martinez de las Heras, Blanca
Rubio-Aparicio, Pedro M
Mazorra Roig, Paula
López Almaraz, Ricardo
RUBIO-SAN-SIMON, Alba
Moreno, Lucas
author_role author
author2 Rubio-Aparicio, Pedro M
Mazorra Roig, Paula
López Almaraz, Ricardo
RUBIO-SAN-SIMON, Alba
Moreno, Lucas
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Martínez de las Heras B] Pediatric Hemato-Oncology Department, Hospital Universitario y Politécnico La Fe, European Reference Network PAEDCAN member, Valencia, Spain. Clinical and Translational Oncology Research Group, Investigation Institute La Fe, Valencia, Spain. [Rubio Aparicio PM] Pediatric Hemato-Oncology Department, Hospital Universitario La Paz, European Reference Network PAEDCAN member, Madrid, Spain. [Rubio San Simón A] Pediatric Hemato-Oncology Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Moreno L, Mazorra P] Servei de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. European Reference Network PAEDCAN member, Barcelona, Spain. [López Almaraz R] Pediatric Onco-Hematology Unit, Hospital Cruces, and Pediatric Oncology Group
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Infants
Neuroblastoma - Tractament
Neuroblastoma - Recaiguda
NAMED GROUPS::Persons::Age Groups::Child
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma
Other subheadings::Other subheadings::/therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma
Otros calificadores::Otros calificadores::/terapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
topic Infants
Neuroblastoma - Tractament
Neuroblastoma - Recaiguda
NAMED GROUPS::Persons::Age Groups::Child
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma
Other subheadings::Other subheadings::/therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma
Otros calificadores::Otros calificadores::/terapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
description Immunotherapy; Neuroblastoma; Relapse
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11351/13792
url http://hdl.handle.net/11351/13792
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical and Translational Oncology;27
https://doi.org/10.1007/s12094-025-03853-w
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404015877423104
spelling Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive diseaseMartinez de las Heras, BlancaRubio-Aparicio, Pedro MMazorra Roig, PaulaLópez Almaraz, RicardoRUBIO-SAN-SIMON, AlbaMoreno, LucasInfantsNeuroblastoma - TractamentNeuroblastoma - RecaigudaNAMED GROUPS::Persons::Age Groups::ChildDISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::NeuroblastomaOther subheadings::Other subheadings::/therapyDISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, LocalDENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niñoENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastomaOtros calificadores::Otros calificadores::/terapiaENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica localImmunotherapy; Neuroblastoma; RelapseImmunoteràpia; Neuroblastoma; RecaigudaInmunoterapia; Neuroblastoma; RecaídaPurpose Outcome for children with refractory and relapse/progressive high-risk neuroblastoma (HR-NB) remains poor, without an internationally agreed standard second-line approach. Heterogeneity in patients’ disease and treatment strategies challenges clinical management. The survival rate for patients with resistant disease does not exceed 20% at 5 years. The study’s aim was to analyze refractory and progressive HR-NB patients in a real-world setting to evaluate current clinical practices and optimize future approaches. Methods Data from patients diagnosed with refractory and relapse/progressive (R/R-P) HR-NB between January 2019 and December 2021 at six of the major Spanish neuroblastoma treating hospitals were collected and analyzed. Results A total of 67 episodes of R/R-P HR-NB were included. Treatments applied included chemotherapy (97%), immunotherapy (48%), consolidation (21%), local treatment (surgery and/or radiotherapy) (45%) and maintenance (16%), and were administered within a clinical trial (CT) in 34% of the episodes. Biopsy was performed in 37% of the tumors and 30% were profiled. Event-free survival (EFS) in our cohort was 20.9% and overall survival (OS) 32%. Significant survival advantage (in both OS and EFS) was observed in refractory episodes compared to relapse/progressive, in first events compared to successive, and when response or disease stabilization was achieved. MYCN status, presence of lymph node metastases, use of irinotecan or topotecan, and radiotherapy were also univariate predictors of OS. Conclusions Treatment of refractory and relapse/progressive HR-NB is highly heterogeneous. We confirm a poor outcome, although certain epidemiological and treatment-related factors have prognostic value. Molecular profiling and inclusion in CTs should be improved.This study has been co-funded by Instituto de Salud Carlos III (ISCIII) through the project ‘ICI21/00098’ with funds from Plan de Recuperación, Transformación y Resiliencia and ‘Funded by the European Union - NextGenerationEU’.SpringerInstitut Català de la Salut[Martínez de las Heras B] Pediatric Hemato-Oncology Department, Hospital Universitario y Politécnico La Fe, European Reference Network PAEDCAN member, Valencia, Spain. Clinical and Translational Oncology Research Group, Investigation Institute La Fe, Valencia, Spain. [Rubio Aparicio PM] Pediatric Hemato-Oncology Department, Hospital Universitario La Paz, European Reference Network PAEDCAN member, Madrid, Spain. [Rubio San Simón A] Pediatric Hemato-Oncology Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Moreno L, Mazorra P] Servei de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. European Reference Network PAEDCAN member, Barcelona, Spain. [López Almaraz R] Pediatric Onco-Hematology Unit, Hospital Cruces, and Pediatric Oncology GroupVall d'Hebron Barcelona Hospital Campus202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/11351/13792Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésClinical and Translational Oncology;27https://doi.org/10.1007/s12094-025-03853-wAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/137922026-06-12T09:38:37Z
score 15.812429

Similares en LA Referencia